Brief Analysis of China's Export of Raw Materials to Europe and America in the Third Quarter of 2013
As a major exporter of raw materials, China may encounter no small problem in entering the European and American markets. A few days ago, the reporter learned from the China Pharmaceutical (22.36, 0.49, 2.24) Health Products Import and Export Chamber of Commerce (hereinafter referred to as the "Medical Insurance Chamber of Commerce") that in the first half of the year, my country's pharmaceutical trade import and export volume reached US $43.237 billion billion, a year-on-year increase of 10.28 percent. However, from the third quarter onwards, China's API exports to Europe and the United States may enter the most difficult period.
In the first half of this year, the global economic growth momentum was insufficient, and the international market demand has not been fundamentally improved, resulting in a decline in international pharmaceutical trade. In this context, the international and domestic situation facing the development of my country's pharmaceutical foreign trade has become more severe, which is embodied in the prominent contradiction of overcapacity, increasing downward pressure on the economy, sluggish external demand, rising costs, and increasing trade frictions.
At the same time, Xu Ming, vice president of the Medical Insurance Chamber of Commerce, also said frankly that in the second half of the year, my country's pharmaceutical foreign trade may enter a relatively long and complex period, and unstable and uncertain factors will increase. In particular, the traditional raw materials in the European and American markets close to saturation, low prices, weak growth. Next, when the market demand in Europe and the United States is still difficult to change significantly, China's API exports to Europe and the United States may enter the most difficult period in the third quarter.
According to the analysis of the Medical Insurance Chamber of Commerce, the main characteristics of China's pharmaceutical foreign trade in the near future are: the continued downturn in developed markets and strong demand in emerging markets; the further optimization of export structure, the growth of export transformation tension, the sharp growth of medical devices and characteristic raw materials, and the strong growth of western medicine preparations; the decline of cost advantage, Weakening the market competitiveness of medical dressings, disposable consumables and other products.
"In the context of the global economic downturn and sluggish pharmaceutical demand, emerging markets have become the only way out for my country's API export growth." Xu Ming analysis. Data show that in the first half of China's bulk API exports to emerging markets increased by 10.03. Among them, large and medium-sized pharmaceutical companies have increased their efforts to develop emerging markets and African markets, and the number of top 100 pharmaceutical companies exporting emerging markets has increased by 12.2.